» Articles » PMID: 10609530

Feasibility of an Outpatient and Home Parenteral Antibiotic Therapy (OHPAT) Programme in Tayside, Scotland

Overview
Journal J Infect
Date 1999 Dec 28
PMID 10609530
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Outpatient and home parenteral antibiotic therapy (OHPAT) is under-utilized in the U.K. We performed a feasibility study over a 5-month period in a regional U.K. infection unit. After exclusions, 183 antibiotic treated patients were evaluated. Ninety-five received intravenous (i.v.) therapy, of whom 32 received at least 4 days. Prolonged i.v. therapy was most frequent in soft tissue infections. In these patients, length of stay and duration of i.v. treatment were correlated (r = 0.74, 0.51-0.87). Eighty-three (86%) of patients who received IV therapy judged OHPAT to be an acceptable alternative to hospitalization. Those who did not were older (mean age 64 vs. 46 years, P<0.001) and were less likely to have a carer willing to administer the antibiotic at home (8/28 vs. 117/151, P<0.001). Twenty-five of 32 (79%) patients treated with prolonged parenteral therapy and 27/95 (28%) treated with any length of parenteral therapy met criteria for OHPAT. Thirteen of these were safely and successfully managed as outpatients by ward staff, OHPAT is an acceptable alternative to inpatient therapy in Tayside and may reduce the duration of hospitalization or prevent admission in certain patients.

Citing Articles

Clinical and cost-effectiveness, safety and acceptability of ommunity ntraenous ntibiotic ervice models: CIVAS systematic review.

Mitchell E, Czoski Murray C, Meads D, Minton J, Wright J, Twiddy M BMJ Open. 2017; 7(4):e013560.

PMID: 28428184 PMC: 5775457. DOI: 10.1136/bmjopen-2016-013560.


Self-administered outpatient parenteral antimicrobial therapy: a report of three years experience in the Irish healthcare setting.

Kieran J, OReilly A, Parker J, Clarke S, Bergin C Eur J Clin Microbiol Infect Dis. 2009; 28(11):1369-74.

PMID: 19697069 DOI: 10.1007/s10096-009-0794-5.